Promis Diagnostics has announced EarlyTect BCD, a novel non-invasive test for detecting bladder cancer in individuals with hematuria.
The US Food and Drug Administration (FDA) has approved this ground-breaking test. The most prevalent symptom associated with bladder cancer is hematuria or the presence of blood in the urine.
EarlyTect BCD is specifically intended to identify PENK methylation, a unique epigenetic biomarker significantly associated with bladder cancer.
The test can accurately identify the presence of PENK methylation, which is regularly found in the urine DNA of persons with bladder cancer, distinguishing them from hematuria patients who do not have the disease, by analyzing the urine DNA of patients with hematuria.
EarlyTect BCD is a substantial advancement in bladder cancer diagnostics, offering a dependable and non-invasive technique for early detection.
This ground-breaking diagnostic has the potential to improve patient outcomes by allowing for more prompt interventions and eliminating the need for invasive procedures.
